Skip to main content
Journal of Genetic Engineering and Biotechnology
Fig. 1 | Journal of Genetic Engineering and Biotechnology

Fig. 1

From: Optimization of recombinant antibody production based on the vector design and the level of metabolites for generation of Ig- producing stable cell lines

Fig. 1

Schematic representation of the plasmid vectors pOpti-L-MluI (A), pSK-EF1-H-BGH (B), pBiPr-HL–ht (C), pBiPr-HL–hh (D), pOpti-L-IRES(Short)-H (E), and pOpti-L-IRES(Long)-H (F). VH and VL, variable domain coding sequences of HC and LC of the mAb with own Kozak sequences and leader peptides, respectively; CH and CL, constant domain coding sequences of the HC and LC of the mAb, respectively; EMCV IRES, IRES from the encephalomyocarditis virus (EMCV) for cap-independent translation of DHFR and HC of the mAb; TKpA, the Herpes Simplex Virus thymidine kinase polyadenylation signal for proper termination and processing of the recombinant transcript; hEF1-HTLV promoter, hybrid composite promoter comprising the Elongation Factor-1α (EF-1α) core promoter1 and the R segment and part of the U5 sequence (R-U5′) of the Human T-Cell Leukemia Virus (HTLV) Type 1 Long Terminal Repeat2; LinkS, short variant EMCV IRES (distance 54 b.p. between TGA LC and EMCV IRES beginning); LinkL, long variant EMCV IRES (88 b.p.)

Back to article page